Diabetic Neuropathic Pain - Pipeline Insight, 2024

This “Diabetic Neuropathic Pain- Pipeline Insight, 2024” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Diabetic Neuropathic Pain pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Diabetic Neuropathic Pain: Understanding

Diabetic Neuropathic Pain: Overview

Diabetic neuropathic pain is a common complication of diabetes mellitus, characterized by chronic, often debilitating pain that affects the peripheral nerves. The signs and symptoms of diabetic neuropathic pain can vary widely, but commonly include tingling, burning, shooting pain, numbness, and hypersensitivity in the affected areas, typically starting in the feet and gradually progressing to involve the hands and other parts of the body. Patients often experience heightened pain at night, which can significantly disrupt sleep and quality of life.

The causes and pathophysiology of diabetic neuropathic pain are multifactorial. Chronic high blood sugar levels in diabetes can lead to nerve damage (neuropathy) through various mechanisms, including inflammation, oxidative stress, and metabolic imbalances. Additionally, vascular complications associated with diabetes can impair blood flow to the nerves, exacerbating nerve damage. Genetic predisposition and lifestyle factors such as smoking and alcohol consumption can also contribute to the development and progression of diabetic neuropathy.

Diagnosis of diabetic neuropathic pain involves a thorough medical history, physical examination, and often nerve conduction studies or electromyography to assess nerve function. Blood tests may be performed to evaluate glucose control and rule out other causes of neuropathy.

Diabetic neuropathic pain treatment aims to alleviate pain, improve nerve function, and manage underlying diabetes. This may involve a combination of medications such as antidepressants, anticonvulsants, and analgesics to manage pain, along with lifestyle modifications such as blood sugar control, regular exercise, and avoiding smoking and excessive alcohol intake. Physical therapy, occupational therapy, and alternative therapies like acupuncture may also be beneficial in managing symptoms and improving quality of life for individuals with diabetic neuropathic pain.

"Diabetic Neuropathic Pain- Pipeline Insight, 2024" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Diabetic Neuropathic Pain pipeline landscape is provided which includes the disease overview and Diabetic Neuropathic Pain treatment guidelines. The assessment part of the report embraces, in depth Diabetic Neuropathic Pain commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diabetic Neuropathic Pain collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Diabetic Neuropathic Pain R&D. The therapies under development are focused on novel approaches to treat/improve Diabetic Neuropathic Pain.

Diabetic Neuropathic Pain Emerging Drugs Chapters

This segment of the Diabetic Neuropathic Pain report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Diabetic Neuropathic Pain Emerging Drugs

Cemdomespib: Biogen

Cemdomespib is a is a highly potent and selective, oral, small molecule C-terminal modulator of Hsp90. Cemdomespib is hypothesized to bind the C-terminus of Hsp90 and lead to increased transcription of cytoprotective and molecular chaperone genes including Hsp70. HSP90 modulation and HSP70 induction have the potential to reduce diabetic nerve pain. Currently, the drug is in Phase II stage of its development for the treatment of Diabetic neuropathic pain.

LX9211: Lexicon Pharmaceuticals

LX9211 is an orally-delivered small molecule compound. The scientists identified the target of LX9211, adapter-associated kinase 1, or AAK1, in target discovery efforts based on their discovery that mice lacking AAK1 exhibited increased resistance to induced neuropathic pain in preclinical models. LX9211 is discovered within the drug discovery alliance with Bristol-Myers Squibb from which Lexicon Pharmaceuticals hold exclusive development and commercialization rights. Preclinical studies of LX9211 demonstrated central nervous system penetration and reduction in pain behavior in models of neuropathic pain without affecting opiate pathways. LX9211 has received Fast Track designation from the FDA for development in diabetic peripheral neuropathic pain. Currently, the drug is in Phase II stage of its development for the treatment of Diabetic neuropathic pain.

AJH-2947: JMackem

AJH-2947 is a novel investigational small molecule candidate being developed by JMackem. The drug candidate are TRPV1 receptor antagonists. Presently Phase-I clinical trials in Diabetic neuropathies is going on in South Korea. AJH-2947 is administered orally. Currently, the drug is in Phase I stage of its development for the treatment of Diabetic neuropathic pain.

Diabetic Neuropathic Pain: Therapeutic Assessment

This segment of the report provides insights about the different Diabetic Neuropathic Pain drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Diabetic Neuropathic Pain

• There are approx. 10+ key companies which are developing the therapies for Diabetic Neuropathic Pain. The companies which have their Diabetic Neuropathic Pain drug candidates in the most advanced stage, i.e. phase II include, Lexicon Pharmaceuticals.

Phases

This report covers around 12+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Diabetic Neuropathic Pain pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Diabetic Neuropathic Pain: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Diabetic Neuropathic Pain therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diabetic Neuropathic Pain drugs.

Diabetic Neuropathic Pain Report Insights

• Diabetic Neuropathic Pain Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Diabetic Neuropathic Pain Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Diabetic Neuropathic Pain drugs?
• How many Diabetic Neuropathic Pain drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Diabetic Neuropathic Pain?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Diabetic Neuropathic Pain therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Diabetic Neuropathic Pain and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Lexicon Pharmaceuticals
• Biogen
• JMackem
• Zhejiang Hanmai Pharmaceutical Technology Co., Ltd.
• Eli Lilly and Company
• Lateral Pharma Pty Ltd
• Tris Pharma, Inc.

Key Products

• LX9211
• Cemdomespib
• AJH-2947
• YJ001
• LY3857210
• LAT8881
• GRT6005

This product will be delivered within 2 business days.